JP2019537424A5 - - Google Patents

Download PDF

Info

Publication number
JP2019537424A5
JP2019537424A5 JP2019512267A JP2019512267A JP2019537424A5 JP 2019537424 A5 JP2019537424 A5 JP 2019537424A5 JP 2019512267 A JP2019512267 A JP 2019512267A JP 2019512267 A JP2019512267 A JP 2019512267A JP 2019537424 A5 JP2019537424 A5 JP 2019537424A5
Authority
JP
Japan
Prior art keywords
amino acid
protein
recombinant protein
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019512267A
Other languages
English (en)
Japanese (ja)
Other versions
JP7183149B2 (ja
JP2019537424A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/049894 external-priority patent/WO2018045308A1/en
Publication of JP2019537424A publication Critical patent/JP2019537424A/ja
Publication of JP2019537424A5 publication Critical patent/JP2019537424A5/ja
Priority to JP2022186724A priority Critical patent/JP7500692B2/ja
Application granted granted Critical
Publication of JP7183149B2 publication Critical patent/JP7183149B2/ja
Priority to JP2024091170A priority patent/JP2024123036A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019512267A 2016-09-02 2017-09-01 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用 Active JP7183149B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022186724A JP7500692B2 (ja) 2016-09-02 2022-11-22 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用
JP2024091170A JP2024123036A (ja) 2016-09-02 2024-06-05 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383267P 2016-09-02 2016-09-02
US62/383,267 2016-09-02
PCT/US2017/049894 WO2018045308A1 (en) 2016-09-02 2017-09-01 Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022186724A Division JP7500692B2 (ja) 2016-09-02 2022-11-22 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用

Publications (3)

Publication Number Publication Date
JP2019537424A JP2019537424A (ja) 2019-12-26
JP2019537424A5 true JP2019537424A5 (cg-RX-API-DMAC7.html) 2020-09-17
JP7183149B2 JP7183149B2 (ja) 2022-12-05

Family

ID=59887401

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019512267A Active JP7183149B2 (ja) 2016-09-02 2017-09-01 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用
JP2022186724A Active JP7500692B2 (ja) 2016-09-02 2022-11-22 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用
JP2024091170A Pending JP2024123036A (ja) 2016-09-02 2024-06-05 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022186724A Active JP7500692B2 (ja) 2016-09-02 2022-11-22 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用
JP2024091170A Pending JP2024123036A (ja) 2016-09-02 2024-06-05 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用

Country Status (11)

Country Link
US (3) US11338033B2 (cg-RX-API-DMAC7.html)
EP (1) EP3506938A1 (cg-RX-API-DMAC7.html)
JP (3) JP7183149B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240042570A (cg-RX-API-DMAC7.html)
CN (2) CN110167585B (cg-RX-API-DMAC7.html)
AU (2) AU2017321883B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019004189A2 (cg-RX-API-DMAC7.html)
CA (1) CA3035443A1 (cg-RX-API-DMAC7.html)
IL (3) IL265121B2 (cg-RX-API-DMAC7.html)
SG (2) SG11201901790YA (cg-RX-API-DMAC7.html)
WO (1) WO2018045308A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054639A1 (en) 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus vaccines
KR20240042570A (ko) * 2016-09-02 2024-04-02 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도
GB2578163A (en) * 2018-10-19 2020-04-22 Univ Pretoria Plant produced avian influenza antigens and their uses in diagnostic assays and devices
US12433943B2 (en) 2019-02-08 2025-10-07 University Of Washington Nanoparticle-based influenza virus vaccines and uses thereof
EP4110384A4 (en) * 2020-02-26 2024-07-31 The Wistar Institute of Anatomy and Biology COMPOSITIONS CONTAINING SELF-ASSEMBLING VACCINES AND METHODS OF USE THEREOF
CN111560074B (zh) * 2020-03-20 2021-07-09 中山大学 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
JP2024511206A (ja) 2021-03-26 2024-03-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
WO2022200582A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
US20250281595A1 (en) 2021-06-28 2025-09-11 Glaxosmithkline Biologicals Sa Novel influenza antigens
WO2023044388A1 (en) * 2021-09-16 2023-03-23 Emergent Product Development Gaithersburg Inc. Vaccine compositions
WO2023061993A1 (en) 2021-10-13 2023-04-20 Glaxosmithkline Biologicals Sa Polypeptides
GB202219228D0 (en) 2022-12-20 2023-02-01 Glaxosmithkline Biologicals Sa Novel influenza antigens
CN115850396B (zh) * 2022-12-22 2024-02-06 北京吉诺卫生物科技有限公司 一种rsv纳米颗粒疫苗及其制备方法与应用
WO2024131862A1 (zh) * 2022-12-22 2024-06-27 北京吉诺卫生物科技有限公司 一种rsv疫苗及其制备方法与应用
WO2024163912A2 (en) * 2023-02-03 2024-08-08 The Children's Medical Center Corporation Vaccine and therapeutic protein delivery compositions comprising fusion proteins
WO2024167855A1 (en) 2023-02-06 2024-08-15 Emergent Product Development Gaithersburg Inc. Influenza hemagglutinin constructs and compositions
WO2024197134A1 (en) * 2023-03-21 2024-09-26 President And Fellows Of Harvard College Coronavirus spike protein-based vaccines

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
ES2307093T3 (es) 2001-10-01 2008-11-16 THE GOVERNMENT OF THE USA, AS REPR. BY SECRETARY, DEPT. HEALTH & HUMAN SERVICES, NAT. INST OF HEALTH Desarrollo de un vacuna preventiva para la infeccion por filovirus en primates.
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
AU2003228962A1 (en) 2002-05-10 2003-11-11 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
EP2351770A1 (en) 2002-07-17 2011-08-03 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
DE60333306D1 (de) 2002-08-30 2010-08-19 Biorexis Pharmaceutical Corp Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
CA2529647C (en) 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
GB0319797D0 (en) 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
US7897408B2 (en) 2005-09-12 2011-03-01 Japan Science And Technology Agency Method for producing CdS-apoferritin and ZnS-apoferritin complexes
EP2476432B1 (en) 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
JP2010514439A (ja) 2006-12-29 2010-05-06 インスティティ パスツール オブ シャンハイ インフルエンザヘマグルチニンで偽型化したレンチウイルス及びその使用方法
EP2160198A2 (en) 2007-05-31 2010-03-10 Statens Serum Institut Influenza vaccines
US8778847B2 (en) 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
CA2696764A1 (en) 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
EP2235043A2 (en) 2008-02-01 2010-10-06 Alpha-O Peptides AG Self-assembling peptide nanoparticles useful as vaccines
JP5382489B2 (ja) 2008-03-29 2014-01-08 国立大学法人 奈良先端科学技術大学院大学 円偏光発光性ナノ微粒子
US20110177122A1 (en) 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
JP2012521786A (ja) * 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
RU2579903C2 (ru) 2009-09-22 2016-04-10 Медикаго Инк. Способ получения вирусоподобных частиц растений
US20120219584A1 (en) 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
JP2013520167A (ja) 2010-02-18 2013-06-06 テクノヴァックス,インコーポレイテッド 万能ウイルス様粒子(vlp)インフルエンザワクチン
CA2821492A1 (en) * 2010-12-13 2012-06-21 The University Of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
EP2758075B1 (en) 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
CA2849822C (en) 2011-09-23 2021-05-11 Gary J. Nabel, M.D. Novel influenza hemagglutinin protein-based vaccines
JP6294828B2 (ja) * 2011-11-28 2018-03-14 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. インフルエンザウイルスワクチンおよびその使用
WO2013177444A2 (en) 2012-05-23 2013-11-28 The Board Of Trustees Of The Leland Stanford Junior University Influenza vaccine constructs
SG11201504728RA (en) * 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
MY190097A (en) * 2013-05-30 2022-03-28 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
WO2015054639A1 (en) 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus vaccines
SI3063273T1 (sl) * 2013-10-28 2020-03-31 Blue Sky Vaccines Gmbh Vektor virusa gripe za viroterapijo
EP3148578B1 (en) 2014-05-27 2022-07-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Stabilized influenza hemagglutinin stem region trimers and uses thereof
BR112016030577A8 (pt) 2014-07-10 2021-07-20 Janssen Vaccines & Prevention Bv polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes
US9969986B2 (en) 2014-08-08 2018-05-15 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
AU2015373928B2 (en) 2014-12-31 2019-10-17 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Novel multivalent nanoparticle-based vaccines
EP3474893A1 (en) * 2016-06-27 2019-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
KR20240042570A (ko) * 2016-09-02 2024-04-02 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도
WO2021231729A1 (en) * 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza

Similar Documents

Publication Publication Date Title
JP2019537424A5 (cg-RX-API-DMAC7.html)
JP2023018073A5 (cg-RX-API-DMAC7.html)
US11793871B2 (en) Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
ES2839880T3 (es) Vacuna contra el VRS
TWI874544B (zh) 變異型rsv f蛋白質及其利用
Ravin et al. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency
WO2012163289A1 (zh) 包含白喉毒素无毒突变体crm197或其片段的融合蛋白
KR102777000B1 (ko) 인플루엔자 바이러스 백신 및 이의 용도
CN105452270A (zh) 流行性感冒病毒疫苗及其用途
JP2015509707A5 (cg-RX-API-DMAC7.html)
JP2018531578A5 (cg-RX-API-DMAC7.html)
US20160000901A1 (en) Compositions and Methods for the Production of Virus-Like Particles
CN107344969A (zh) 一种纳米流感疫苗及构建方法和应用
CN111556896A (zh) 交叉免疫抗原疫苗及其制备方法
JP7545955B2 (ja) インフルエンザhaスプリットワクチンの製造方法
WO2018175560A1 (en) Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain
CN110201183A (zh) 一种可同时递送抗原和免疫增强剂的纳米制剂
WO2020246584A1 (ja) ペプチド核酸を基盤としたアジュバント
CN106337038B (zh) 一种通过转肽酶剪切制备疫苗的方法及其应用
Kotlyarov et al. Development of recombinant vaccine against A (H1N1) 2009 influenza based on virus-like nanoparticles carrying the extracellular domain of M2 protein
CN103242426B (zh) 禽流感病毒h5n1亚型限制性ctl表位多肽及其应用
WO2024199469A1 (zh) 具有稳定融合前构象的呼吸道合胞病毒f蛋白